3.1 Details of perpetual securities:

In the financial year 2018-19, the Company has invested in unsecured subordinated perpetual securities issued by Aprica Healthcare Limited, its subsidiary company. These securities are redeemable at the issuer's option and carry non-cumulative interest coupon at the rate of dividend paid on the issuer's ordinary shares. No interest will be payable if the issuer does not pay any dividend on its ordinary shares for the Financial Year. The Company has classified this investment as Equity Instrument and has accounted at cost as per Ind AS 27 Separate Financial Statements.

3.2 Lock in period for Eris M. J. Biopharm Private Limited (Formerly Known as Kinedex Healthcare Private Limited)

As per share purchase & shareholders agreement, For a period of 10 (ten) years , Eris Lifesciences Limited and M.J. Biopharm Private Limited shall not, directly or indirectly, transfer or attempt to transfer all or any of the Equity Shares (or any interest therein) held by it to any Person.

3.3 The networth of this subsidiary is less than the exposure in the form of investment in equity instrument and unsecured perpetual securities of the Company in the said subsidiary as at March 31, 2024.

However in view of the strategic nature of the investment in this Company and also considering the future business plans and cash flow projections of the Company the same is valued at cost and no impairment allowance is required to be provided for.

3.4 Swiss Parenterals Limited 22,32,657 Shares are pledged against Non Convertible debentures issued.

3.5 Compulsory convertible debentures

The Company has invested in Compulsory convertible debentures of Eris Oaknet Healthcare Private Limited, its subsidiary company. These securities are redeemable at the issuer's option and carry non-cumulative interest coupon at the rate of 0.01% payable on expiry of lock in period. These securities are having maturity of nine years and eleven months. The Company has classified this investment as Equity Instrument and has accounted at cost as per Ind AS 27 Separate Financial Statements.

* Pursuant to the Scheme of Budgetary Support under Goods and Services Tax [GST] Regime the Company is entitled to avail certain benefits for the goods manufactured in the state of Assam. The requisite conditions have been fulfilled by the Company and the Company is entitled to receive such income. Required claims have been filled with the regulatory authority within the stipulated timeline.

*Vide letter dated June 29, 2022, the BSE Limited and National Stock Exchange of India Ltd. approved the reclassification of Mr. Himanshu Jayantbhai Shah from the 'Promoter' Category to the 'Public' Category. He is holding shares 4,50,926 as on March 31, 2024 (Previous year 4,75,801).

11.4 Terms / Rights attached to the equity shares:

The Company has only one class of equity shares having a par value of '1 per share. Each holder of equity share is eligible for one vote per share. The final dividend, if any, proposed by the Board of Directors of the Company is subject to the approval of the shareholders in the ensuing Annual General Meeting. In the event of liquidation, the equity shareholders are eligible to receive the remaining assets of the Company after distribution of all preferential amounts, in proportion to their shareholding.

11.5 Share options granted under the Company's employee share option plan:

The Company recognizes compensation expense relating to share-based payments in statement of profit and loss using fair value in accordance with Ind AS 102, share based payment. The estimated fair value of awards is charged to income on a straightline basis over the requisite service period for each separately vesting portion of the award as if the award was in-substance multiple awards with a corresponding increase to share options outstanding account.

Nature and purpose of reserves :

Retained Earnings : Retained Earnings are the profits that the Company has earned till date less any transfer to general reserve, dividends and other distributions to shareholder.

Share based payment reserve : The fair value of equity-settled share based payment transactions with employees is recognised in Statement of Profit and Loss with corresponding credit to Share based payment reserve. Such amount is available for utilisation in accordance with the provisions of the Companies Act, 2013.

Capital redemption reserve: The Company is required to create capital redemption reserve in accordance with provisions of the Companies Act 2013 for buy back of shares. The reserve can be utilised in accordance with the provisions of section 69 of the Companies Act, 2013.

Security premium: The amount received in excess of the par value of equity shares has been classified as securities premium. Such amount is available for utilisation in accordance with the provisions of the Companies Act, 2013.

Provision for sales returns:

"The Company, as a trade practice, accepts returns from market which are primarily in the nature of expired or near expiry products. Provision is made for such returns on the basis of historical experience, market conditions and specific contractual terms.

At the time of recognising provision for sales return expected reimbursement towards likely sales return is also recognied, which is included in other current assets for the products expected to be returned." * Capital subsidy represents Central Capital Investment Subsidy received during the financial year 2018-19 under North East Industrial & Investment Promotion Policy (NEIIPP). It is recognised in statement of profit or loss account over the periods and in the proportions in which depreciation expense on those assets is recognised.

Contract assets are initially recognised for revenue from sale of goods. Contract liabilities are on account of the upfront revenue received from customer for which performance obligation has not yet been completed.

The performance obligation is satisfied when control of the goods or services are transferred to the customers based on the contractual terms. Payment terms with customers vary depending upon the contractual terms of each contract.

Note 26: Code of Social Security

The Parliament of India has approved the Code on Social Security, 2020 ("the Code") which, inter alia, deals with employee benefits during employment and post employment. The Code has been published in the Gazette of India. The effective date of the Code is yet to be notified and the rules for quantifying the financial impact are also yet to be issued. In view of this, the impact of the change, if any, will be assessed and recognised post notification of the relevant provisions.

Note 27: Mergers and acquisitionNote 27.1 a : Acquisition of Eris Oaknet Healthcare Private Limited (Formerly known as Oaknet Healthcare Private Limited)

During the the Financial Year 2022-23, the Company has completed acquisition of 100% stake in Eris Oaknet Healthcare Private Limited (formerly known as Oaknet Healthcare Private Limited) and obtained control on May 12, 2022 from its erstwhile shareholders for a consideration of ' 6,554.90 Million (including transaction cost).

EOHPL's business predominantly comprised of brands in Dermatology and Women's Health segments.

Note 27.1 b : Operation integration of the domestic formulations business and brand transfer of subsidiary Eris Oaknet Healthcare Private Limited (EOHPL)

"During the year, the Company has operationally integrated the domestic formulations business of its subsidiary Eris Oaknet Healthcare Private Limited (EOHPL) vide a subsisting Royalty based Trademark License agreement which confers upon ELL the rights to use the trademarks owned by EOHPL. Further, during the quarter 2, pursuant to a Deed of assignment of Trademark entered into between Eris Oaknet Healthcare Private Limited (EOHPL) and Eris Lifesciences Limited (ELL), ELL has acquired all the rights, title and interest to the certain trademarks owned by the EOHPL, for a consideration of ' 3,401.04 million (including transaction costs), being the Net book value of the said trademarks on the date of the transfer."

Note 27.2 : Amalgamation and Demerger of subsidiary companies

During the Financial Year 2022-23, on December 23, 2022 Honorable National Company Law Tribunal has approved the scheme of arrangement ("the Scheme") under section 230 and 232 of the Companies Act, 2013. Pursuant to the Scheme, one of the divisions of Eris Healthcare Private Limited - a wholly owned subsidiary of Eris Lifesciences Limited (the "Company") as represented by certain brands and related assets and liabilities is demerged and merged into Aprica Healthcare Limited - a wholly owned subsidiary of the Company with effect from April 1, 2021.

"Equity Shares of face value ' 10 each credited as fully paid up of Aprica Healthcare Limited in the ratio of 1 Equity Share of the face value of ' 10 each of Aprica Healthcare Limited for every 2 equity shares of ' 10 credited as fully paid-up held by such equity shareholders in Eris Healthcare Private Limited before capital reduction.

Note 27.3 : Acquisition of Brands of Dr. Reddy's Laboratories Limited

During the Financial Year 2022-23, the Company has completed acquisition of 9 brands of Dr. Reddy's Laboratories Limited a consideration of ' 2,750 Million.

Note 27.4 : Acquisition of the Branded Formulations India business units of Nephrology and Dermatology from Biocon Biologics Limited

During the year the Company has completed acquisition of the Branded Formulations India business units of Nephrology and Dermatology from Biocon Biologics Limited for a consideration of ' 3,660.00 million on a slump sale basis. The acquisition was completed on November 9, 2023. The Company has determined the fair values of identified assets and liabilities for the purpose of Purchase price allocation.

Goodwill arose in the acquisition of the above said entity because the consideration paid for the combinations effectively included amounts in relation to the benefit of expected synergies, revenue growth, future market development and the assembled workforce. These benefits are not recognised separately from goodwill because they do not meet the recognition criteria for identifiable intangible assets.

Note 27.5 : Acquisition of 51% shares of Swiss Parenterals Limited

During the the year, the Company completed the acquisition of 28,46,639 equity shares representing 51% of equity share capital for an agreegate consideration of ' 6,383 million (including transaction cost) of Swiss Parenterals Limited (SPL) and obtained control on February 15, 2024 from its erstwhile shareholders. The consideration was settled through Cash Consideration of ' 2,000 million and issuance of 43,750 8% Secured Redeemable Non-Convertible Debentures of ' 4,375 million. Subsequent to the year end, the Company has further acquired 10,60,512 shares of SPL representing 19% of its equity share capital of SPL on April 18, 2024 for a consideration of ' 2,375 million.

Note 27.6 : Acquisition of the Branded Formulations India business units from Biocon Biologics Limited

The Company entered into definitive agreement for acquisition of Branded Formulations India business units from Biocon Biologics Limited on March 14,2024. Subsequent to the year end, the Company has completed the acquisition for a consideration of ' 12,420 million on a slump sale basis. The acquisition was completed on April 1, 2024. For the purpose of this acquisition, the Company has availed bridge loan in the form of Commercial Papers of ' 9,750 million having a tenure of 90 days which are listed and unsecured in nature. Current liabilities as on March 31, 2024 includes Commercial Papers of ' 9,750 million which were refinanced by way of issuance of long term non-convertible debentures in June 2024. Funds received was parked in Fixed Deposit as earmarked for the payment of above acquisition.

Note 27.7: Demerger of domestic formulations business of subsidiary Eris Oaknet Healthcare Private Limited (EOHPL)

"Subsequent to the year end, the Board of Directors have approved Composite scheme of arrangement u/s 230 to 232 read with section 66 and other applicable provisions of the Companies Act, 2013, amongst Eris Lifesciences Limited and Eris Oaknet Healthcare Private Limited and their respective Shareholders and Creditors.

The Scheme is subject to necessary statutory and regulatory approvals under the applicable laws, including approval of the jurisdictional Hon'ble National Company Law Tribunal."

Note 28: Employee benefit plansA) Defined contribution plans:

The Company makes contributions towards provident fund, a defined contribution retirement benefit plan for qualifying employees. The provident fund is operated by the Regional Provident Fund Commissioner. The Company recognized ' 112.71 million (Previous Year '81.56 million) for provident fund contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme.

The Company made contributions towards Employees State Insurance Scheme operated by the ESIC Corporation. The Company recognized ' 1.99 million (Previous year '2.40 million) for ESIC contributions in the Statement of Profit and Loss. The contributions payable to these plans by the company are at rates specified in the rules of the scheme."

B) Defined benefit plans:

Actuarial Valuation for Compensated Absences is done as at the year end and the provision is made as per Company rules with corresponding charge to the Statement of Profit and Loss amounting to ' 40.11 million (Previous Year '15.95 million) and it covers all regular employees. Major drivers in actuarial assumptions, typically, are years of service and employee compensation.

"The company makes annual contributions to the Employee's Group Gratuity cash accumulation scheme of the Life Insurance Corporation of India, a funded defined benefit plan for qualifying employees. The Scheme provides for payment to vested employees at retirement/death while in employment or on termination of employment as per the provisions of the Gratuity Act, 1972. Vesting occurs on completion of 4.6 years of service. The present value of the defined benefit obligation and the related current service cost are measured using the Projected Unit Credit Method as per actuarial valuation carried out at the balance sheet date.

The following table sets out the status of the gratuity plan as required under IND AS-19 and the amounts recognized in the Company's financial statements as at March 31, 2024:"

Notes:

1. The plan assets which are managed by Insurance Company viz Life Insurance Corporation of India, details of those funds invested by the insurer are not available with company.

2. The discount rate is based on the prevailing market yields of government of India securities as at the balance sheet date for the estimated term of the obligations.

3. Expected rate of return on plan assets is determined based on the nature of assets and prevailing economic scenario.

4. The estimate of future salary increases considered, takes into account inflation, seniority, promotion, increments and other relevant factors.

5. The expected contribution to be made by company for gratuity during financial year ending March 31, 2025 is '40.53 million (previous year '27.19 million).

(ii) Fair value hierarchy :

Financial assets and financial liabilities measured at fair value in the statement of financial position are grouped into three levels of a fair value hierarchy. The three levels are defined based on the observability of significant inputs to the measurement, as follows:

Level 1: Quoted prices (unadjusted) in active markets for financial instruments.

Level 2: The fair value of financial instruments that are not traded in an active market is determined using valuation techniques which maximise the use of observable market data rely as little as possible on entity specific estimates.

Level 3: If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3.

Determination of fair values: The following are the basis of assumptions used to estimate the fair value of financial assets and liabilities that are measured at fair value on recurring basis :

Investment in mutual funds: The fair values represent net asset value as stated by the issuers of these mutual fund units in the published statements. Net asset values represent the price at which the issuer will issue further units in the mutual fund and the price at which issuers will redeem such units from the investors.

Equity investments: Fair value of Equity investments traded in an active market are determined by reference to their quoted market prices. Other equity investments where quoted prices are not available, fair values are determined by reference to the current market value of net assets or relied upon on valuation report of an valuer.

(iii) Financial risk management:

The Company's activities are exposed to variety of financial risks. These risks include market risk, credit risk and liquidity risk. The Company's overall risk management program seeks to minimize potential adverse effects on the financial performance of the Company through established policies and processes which are laid down to ascertain the extent of risks, setting appropriate limits, controls, continuous monitoring and its compliance.

a) Market risk :

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of change in market prices. The Company is not an active investor in equity markets; it continues to hold certain investments in equity for long term value accretion. Market risk comprises of three type of risks namely interest rate risk, currency risk and other price risk such as equity price risk. The Company is not exposed to currency risk and other price risk whereas the exposure to interest risk is given below: Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of change in market interest rate.

The Company invests in mutual fund schemes of leading fund houses and tax free bonds. Such investments are susceptible to market price risk that arise mainly from changes in interest rate which may impact the return and value of such investments. Investments in mutual funds and tax free bonds amounts to ' 3.26 million and ' 303.35 million as at March 31, 2024 and March 31, 2023 respectively.

b) Credit Risk

The Company is exposed to credit risk, which is the risk that counterparty will default on its contractual obligation resulting in a financial loss to the Company. Credit risk arises majorly from cash and cash equivalents, deposits with banks, Investments as well as credit exposures to customers including outstanding receivables.

Credit Risk Management

Credit risk is the risk of financial loss to the Company if a customer or counter-party fails to meet its contractual obligations, and arises principally from the companies receivables from customers.

Credit risk arises from the possibility that customers may not be able to settle their obligations as agreed. To manage this risk, the Company periodically assesses the financial reliability of customers, taking into account their financial position, past experience and other factors. The Company manages credit risk through credit approvals, establishing credit limits and continuously monitoring the creditworthiness of customers to which the Company grants credit terms in the normal course of business.

Historical trends of impairment of trade receivables do not reflect any significant credit losses. Given that the macro economic indicators affecting customers of the Company have not undergone any substantial change, the Company expects the historical trend of minimal credit losses to continue.

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk is '15,990.90 million and '4,358.63 million as at March 31, 2024 and March 31, 2023 respectively, being the total of the carrying amount of balances with banks, bank deposits, trade receivables, other financial assets, loans and investments excluding equity investments in subsidiaries, and these financial assets are of good credit quality including those that are past due.

c) Liquidity Risk

Liquidity Risk is the risk that the company will not be able to meet its financial obligation as they fall due. Liquidity risk arises because of the possibility that the company could be required to pay its liabilities earlier than expected or encounters difficulty in raising funds to meet commitments associated with financial liabilities as they fall due. The company approach to managing liquidity is to ensure, as far as possible, that it always have sufficient liquidity to meet its liabilities when due. The Company generates cash flows from operations to meet its financial obligations and manages liquidity risk by maintaining sufficient cash and bank balance and availability of funding through adequate amount of committed credit facilities.

(iv) Capital management

The capital structure of the Company consists of equity, debt, cash and cash equivalents. The Company's objective for capital management is to maintain the capital structure which will support the Company's strategy to maximize shareholder's value, safeguarding the business continuity and help in supporting the growth of the Company.

The Company manages its capital structure and makes adjustments to it in the light of changes in economic conditions and the requirements of the financial covenants. To maintain or adjust the capital structure, the Company may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. The Company monitors capital using Debt-Equity ratio, which is net debt divided by total equity. Debt is defined as liabilities comprising interest-bearing loans and borrowings, lease liabilities less cash and bank balances. Adjusted equity comprises all components of equity.

No changes were made in the objectives, policies or processes for managing capital during the years ended March 31, 2024; March 31, 2023.

(v) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates. As at March 31, 2024 , the Company has floating rate borrowings. The Company constantly monitors the credit markets and rebalances its financing strategies to achieve an optimal maturity profile and financing cost.

For the year ended 31 March 2024, every 1% increase or decrease in the floating interest rate component (i.e., Treasury bill) applicable to its borrowings would affect the Company's profit before tax by '55.34 million. (Previous year ' 29.53 million.)"

Note: The Company has received notices from NPPA (National Pharmaceutical Pricing Authority), under DPCO (Drug Price Control Order), 2013 during earlier years. Management does not expect any cash outflow from this matter.

Estimated amount of contracts remaining unexecuted on capital account (net of advances) not provided :

a) '0.62 million for Property Plant & Equipment (Previous year '8.40 million)

b) '2,375 million for acquisition of business

c) '12,420 million for acquisition of shares of subsidiary.

The Company has given corporate guarantee to banks for credit facilities upto '3,050 million (Previous year '1,700 million) availed by its subsidiary Eris Therapeutics Limited. As per the terms of deed of guarantee, the Company undertakes not to divest its ownership interest directly or indirectly in the subsidiary and provide such managerial, technical and financial assistance to ensure continued successful operations of the subsidiary.

The Company has given corporate guarantee to banks for credit facilities upto 'Nil (Previous year '4,350 million) availed by its subsidiary Eris Oaknet Healthcare Private Limited (Formerly known as Oaknet Healthcare Private Limited) as per deed of guarantee, the Company undertakes not to divest its ownership interest directly or indirectly in the subsidiary and provide such managerial, technical and financial assistance to ensure continued successful operations of the subsidiary.

The Company does not expect any outflow of resources in respect of the above.

Note 35: ESOP

The employee compensation cost as per fair value method for the financial year 2023-24 is ' 32.87 million and for financial year 2022-23 is ' 31.21 million.

A. Eris Lifesciences Employee Stock Option Plan 2017' (“ESOP 2017"/ "Plan")

The Company has introduced 'Eris Lifesciences Employee Stock Option Plan 2017' ("ESOP 2017”/ "Plan”) through the resolution passed by the Board of Directors on February 02, 2017 and the same was approved by the shareholders at the extra ordinary general meeting held on February 03, 2017 and subsequently in the eleventh annual general meeting held on September 29, 2017 shareholders ratified the same. Under the scheme, 391,599 (Three lakhs ninety one thousand five hundred ninety nine only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of ' 1 each for an exercise price of ' 451.04. Vesting of the options shall take place over a maximum period of 5 years with a minimum vesting period of 1 year from the date of grant i.e. April 12, 2017. The exercise period would be a maximum of 5 years from the date of vesting of options 1,15,783 and 1,14,736 options have lapsed till March 31, 2024 and March 31, 2023 respectively.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

Method used for accounting of share-based payment plans

The employee compensation cost has been calculated using Black Scholes Option Pricing Model. The assumptions are as stated in the below table.

B. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

*The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,14,102 (Two lakhs fourteen thousand one hundred two only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of '1 each for an exercise price of ' 557.24. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2022. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

C. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,79,568 (Two lakhs seventy nine thousand five hundred sixty eight only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of ' 1 each for an exercise price of ' 510.32. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2023. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

D. Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan")

The Company has introduced 'Eris Lifesciences Long Term Incentive Plan, 2021' ("Employee Stock Option Plan"/ "Plan") through the resolution passed by the Board of Directors on July 29, 2021 and the same was approved by the shareholders at the annual general meeting held on September 01, 2021. Under the scheme 13,58,630 equity shares have been approved in Annual General Meeting out of which, 2,75,597 (Two lakhs seventy five thousand five hundred ninety seven only) equity shares have been granted to eligible employees of the company and each option (after it is vested) is exercisable for one equity share having face value of ' 1 each for an exercise price of ' 728.16. Vesting of the options shall take place over a maximum period of 4 years with a minimum vesting period of 1 year from the date of grant i.e. February 10, 2024. The exercise period would be a maximum of 7 years from the date of vesting of options.

As per the Scheme, the Nomination and Remuneration Committee grants the options to the employees deemed eligible. Pricing Formula

Discount to fair market value of the Equity Shares as on the date of grant.

Notes

(1) Debt represents borrowings and lease liabilities.

(2) Net Profit after tax" means reported amount of "Profit / (loss) for the period" and it does not include items of other comprehensive income.

Earning for Debt Service = Net Profit after taxes Non-cash operating expenses like depreciation and other amortizations Interest other adjustments like loss on sale of Fixed assets etc.

(3) Lease payments, interest and principal repayment for the current year

(4) Tangible net worth deferred tax liabilities Lease Liabilities

Note 37 (B) : Other statutory information

i) . The Company has not advanced or loaned or invested funds to any other person(s) or entity(ies), including foreign

entities (Intermediaries) with the understanding that the Intermediary shall:

(a) directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever by or on behalf of the company (ultimate beneficiaries) or

(b) provide any guarantee, security or the like to or on behalf of the ultimate beneficiaries

ii) . The Company has not received any fund from any person(s) or entity(ies), including foreign entities (funding party) with

the understanding (whether recorded in writing or otherwise) that the Company shall:

(a) directlyorindirectlylend or invest in otherpersons or entities identified in anymannerwhatsoeverby or on behalfofthe funding party (ultimate beneficiaries) or

(b) provide any guarantee, security or the like on behalf of the ultimate beneficiaries.

iii) . Quarterly returns or statements of current assets filed by the Company with banks or financial institutions are in

agreement with the unaudited books of accounts.

iv) . The title deeds of all the immovable properties, (other than immovable properties where the Company is the lessee and

the lease agreements are duly executed in favour of the Company) disclosed in the financial statements included in property, plant and equipment are held in the name of the Company as at the balance sheet date.

v) . The Company does not have any transactions or balances with a Companies struck off under section 248 of the

Companies Act, 2013 or Section 560 of the Companies Act 1956.

vi) . The Company does not have any such transaction which is not recorded in the books of accounts that has been

surrendered or disclosed as income during the year in the tax assessment under the Income Tax Act, 1961.

vii) . Details of Loan given, Investment made and Guarantee given covered u/s 186 (4) of the Companies Act, 2013:

(a) Loan given by the Company to body corporate as at March 31, 2024. (Refer Note 10)

(b) Investment made by the Company as at March 31, 2024. (Refer Note 3)

(c) Guarantee given by the Company as at March 31, 2024. (Refer note 33)

viii) The borrowings obtained by the Company from banks have been applied for the purposes for which such loans was taken.

ix) No proceedings have been initiated on or are pending against the Company for holding benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and Rules made thereunder.

x) The Company has not been declared wilful defaulter by any bank or financial institution or government or any government authority.

xi) The Company has complied with the number of layers prescribed under the Companies Act, 2013

xii) The Company has not traded or invested in crypto currency or virtual currency during the current or previous year.

xiii) The company has not revalued its property, plant and equipment during the current or previous year.

xiv) There are no charges or satisfaction which are yet to be registered with the Registrar of Companies beyond the statutory period.

xv) The Company has used an accounting software for maintaining its books of account for the period April 1, 2023 to December 31, 2023 which had a feature of recording audit trail (edit log) facility and the same had operated throughout the said period for all relevant transactions recorded in the software, except that audit trail was not enabled at the database level to log any direct data changes.

This legacy ERP system was nearing the end of its lifespan and was experiencing significant performance issues. The system's compute capacity and overall infrastructure was insufficient to handle the additional load and overheads associated with the audit trail read/write operations at the database level. Enabling this feature would have further strained the system, potentially leading to crashes and severe disruptions in daily operations.

Hence the Company has migrated to another accounting software (SAP /4HANA) on January 1, 2024 for maintaining its books of accounts which has a feature of recording audit trail (edit log) facility and the same was operational for all relevant transactions recorded in the software, except that, audit trail feature was not enabled for privileged access users for smooth functioning during the migration period.

During the system implementation of the new accounting software (SAP), as part of the system hyper-care period, privileged access was enabled for swift issue resolution. The Company is presently streamlining the process for user provisioning and privileged access to ensure compliance; with a Change Control Mechanism to be instituted shortly."